Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Acquires $236,625.12 in Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par purchased 9,004 shares of Lycia Therapeutics stock in a transaction on Friday, October 30th. The shares were acquired at an average cost of $26.28 per share, for a total transaction of $236,625.12. Following the purchase, the insider owned 6,850,237 shares in the company, valued at approximately $180,024,228.36. This trade represents a 0.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, October 29th, Venrock Healthcare Capital Par acquired 1,000 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $26.33 per share, for a total transaction of $26,330.00.
• On Wednesday, October 28th, Venrock Healthcare Capital Par acquired 15,000 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $25.45 per share, with a total value of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par bought 39,796 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $26.62 per share, with a total value of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par bought 1,952,705 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $18.04 per share, with a total value of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $25.91 per share, for a total transaction of $1,371,649.49.

Lycia Therapeutics Price Performance

NASDAQ:LYCA traded down $1.33 during mid-day trading on Friday, reaching $26.40. The company’s stock had a trading volume of 202,428 shares, compared to its average volume of 857,210. Lycia Therapeutics, Inc. has a twelve month low of $22.19 and a twelve month high of $36.49.

Lycia Therapeutics Company Profile

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.